A Rare Nephrotic Syndrome Related to Chronic Lymphocytic Leukemia: Focal Segmental Glomerulosclerosis.
autoimmune disease and cancer
chronic lymphocytic leukemia (cll)
focal segmental glomerulosclerosis (fsgs)
glomerulonephritis (gn)
immunosuppression
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
accepted:
14
11
2022
entrez:
21
12
2022
pubmed:
22
12
2022
medline:
22
12
2022
Statut:
epublish
Résumé
Chronic lymphocytic leukemia (CLL) is a hematological disease characterized by the proliferation of monoclonal B-lymphocytes. Although autoimmune complications such as autoimmune hemolytic anemia and immune thrombocytopenia are common in CLL patients, nonhematological autoimmune complications are rather rare. The most common renal involvements are membranoproliferative glomerulonephritis and minimal change disease. Focal segmental glomerulosclerosis (FSGS) is predominantly associated with Hodgkin's lymphoma among hematological malignancies. FSGS associated with CLL is rarely reported in the literature, with a poor understanding of the common pathophysiology and a very limited experience with this co-occurrence. Although Rai Stage 1/Binet Stage B CLL, our 61-year-old case, who was diagnosed with secondary FSGS, which is a very rare complication, was treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination. Following the treatment, a complete response was achieved about CLL, and the patient, whose renal findings recovered, is in remission and under follow-up for six years. Although the mechanisms between CLL and autoimmune complications are not fully elucidated, it is usually related to immune disorders like an abnormal T-cell response and polyclonal antibody production. While FSGS is very rare in lymphoma, its co-existence with CLL is reported only in a limited number of case reports. Steroids may be used in these patients; however, in cases not responding to steroids, treatment of the underlying CLL is required.
Identifiants
pubmed: 36540526
doi: 10.7759/cureus.31545
pmc: PMC9754732
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e31545Informations de copyright
Copyright © 2022, Karakus et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Nephrol. 2011 Jul 05;12:33
pubmed: 21729272
Clin J Am Soc Nephrol. 2014 Mar;9(3):626-32
pubmed: 23990165
Am J Kidney Dis. 1994 Jun;23(6):773-83
pubmed: 8203357
Nat Rev Dis Primers. 2017 Jan 19;3:16096
pubmed: 28102226
Semin Oncol. 2006 Apr;33(2):230-9
pubmed: 16616070
Haematologica. 2011 May;96(5):752-61
pubmed: 21242190
Am J Hematol. 2004 Oct;77(2):205-6
pubmed: 15389914
Cancer Immunol Immunother. 2011 Jan;60(1):75-85
pubmed: 20857100
Clin Exp Nephrol. 2006 Dec;10(4):284-9
pubmed: 17186334
Leuk Res. 2009 Mar;33(3):366-7
pubmed: 18930543
Ann Hematol. 2018 Nov;97(11):2153-2161
pubmed: 29946909